Concurrent acne procedures and isotretinoin in 2026 research means adults with persistent acne can, in selected cases, receive certain lasers during isotretinoin treatment under dermatologist supervision. Isotretinoin is an oral drug reserved for severe, scarring, or treatment-resistant acne. Recent studies report faster clearance and better scar scores with combined treatment, without the wound-healing problems once feared. Results remain early and selective, so candidacy depends on acne type, scar type, dose, device, and safety screening.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the 2026 evidence show
- Who is this briefing for
- Does skin tone change the calculation
- What safeguards still apply
What does the 2026 evidence show
A 2026 five-patient case series treated severe inflammatory acne plus atrophic scarring with fixed low-dose isotretinoin at 20 mg per day alongside sequential 1,540-nm nonablative fractional laser, then fractional CO2 and 1,064-nm Nd:YAG. As reported by Cureus, the patients had clearance or improvement without wound-healing complications, keloids, or abnormal scarring, described in the five-patient Cureus case series. A November 2025 study of 675-nm laser found concurrent oral isotretinoin at 0.1-0.3 mg per kg per day produced faster, more pronounced acne vulgaris improvement than laser alone.
As reported by MDPI Healthcare, all patients completed treatment without adverse events or unexpected effects, detailed in the November 2025 Healthcare study. These findings extend the 2017 ASDS consensus summarized by MDedge, which found insufficient evidence to delay manual dermabrasion, superficial peels, cutaneous surgery, laser hair removal, and fractional ablative or nonablative lasers during or after isotretinoin. That consensus still did not recommend mechanical dermabrasion or fully ablative lasers.
Who is this briefing for
Updated acne guidance continues to reserve oral isotretinoin for severe acne, scarring disease, or acne failing standard oral and topical therapy. That group includes many adults with persistent acne who also have redness, uneven texture, or atrophic scars. A prospective split-face trial from Tel Aviv University and Tel Aviv Sourasky Medical Center tested three monthly fractional ablative CO2 sessions on one cheek during isotretinoin and the same treatment on the other cheek six months after stopping the drug.
The concurrent side had significantly lower scar scores, 4.7 plus or minus 2.5 versus 7.7 plus or minus 2.9. In practice, combined care pairs active-acne control with scar treatment in one course. A dermatologist weighs lesion severity, scar depth, prior therapies, keloid history, and sun exposure before suggesting overlap.
Does skin tone change the calculation
Evidence for medium to darker skin remains limited but encouraging. At ASLMS 2025, three Fitzpatrick IV-VI patients taking 60-80 mg per day of isotretinoin received four monthly conservative 1,565-nm nonablative fractional treatments on one side of the face. Medscape reporting on the meeting noted no new or worsening hyperpigmentation, hypopigmentation, or scarring versus control, with patient-reported improvement.
Conservative settings and one-side comparison helped isolate visible color and texture change. Standardized settings are a key caveat. Settings not adjusted by skin type may miss risk in darker skin, so adults should ask whether fluence, density, cooling, and intervals were tailored to their tone.
What safeguards still apply
The strongest concurrent-use signals come from very small samples, such as groups of five and three patients, plus retrospective and case-series designs. As noted in the Tel Aviv University trial record, standardized laser settings not adjusted by skin type limit broad claims, so results do not guarantee safety for every adult, device, or dose. Strict systemic safeguards remain required with isotretinoin.
According to the U.S. National Library of Medicine DailyMed label, patients must avoid pregnancy for one month before, during, and one month after treatment, obtain iPLEDGE REMS authorization, and stop the drug plus report immediately if pregnancy occurs, explained in the DailyMed isotretinoin label. Bring a full medication list, pregnancy-prevention plan, keloid history, and recent sun or tanning history to the dermatology visit.
- Confirm no pregnancy for 1 month before, during, and 1 month after isotretinoin
- Complete iPLEDGE REMS authorization before dispensing
- Stop isotretinoin at once and call the prescriber if pregnancy occurs
- Report to MedWatch at 1-800-FDA-1088 and iPLEDGE at 1-866-495-0654
You Might Also Like
- Treatment Response in the 2026 Cumulative Isotretinoin Dose Trial: A Source-Checked 2026 Briefing for Adults With Persistent Acne
- Cumulative Isotretinoin Dose and Acne Relapse in a 2026 Trial: A Source-Checked 2026 Briefing for Adults With Persistent Acne
- Cumulative Isotretinoin Dose and Acne Relapse in a 2026 Trial: Who Was Studied and Who Was Not for Adults With Persistent Acne